SE0302139D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
SE0302139D0
SE0302139D0 SE0302139A SE0302139A SE0302139D0 SE 0302139 D0 SE0302139 D0 SE 0302139D0 SE 0302139 A SE0302139 A SE 0302139A SE 0302139 A SE0302139 A SE 0302139A SE 0302139 D0 SE0302139 D0 SE 0302139D0
Authority
SE
Sweden
Prior art keywords
sup
novel compounds
therapy
processes
formula
Prior art date
Application number
SE0302139A
Other languages
English (en)
Inventor
Rhonan Ford
Paul Willis
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0302139A priority Critical patent/SE0302139D0/sv
Publication of SE0302139D0 publication Critical patent/SE0302139D0/sv
Priority to JP2006521802A priority patent/JP2007500187A/ja
Priority to CA002532154A priority patent/CA2532154A1/en
Priority to BRPI0413094-4A priority patent/BRPI0413094A/pt
Priority to KR1020067001966A priority patent/KR20060054370A/ko
Priority to EP04749180A priority patent/EP1651610A1/en
Priority to RU2006102127/04A priority patent/RU2006102127A/ru
Priority to AU2004259615A priority patent/AU2004259615A1/en
Priority to US10/566,320 priority patent/US20080058293A1/en
Priority to MXPA06000882A priority patent/MXPA06000882A/es
Priority to PCT/SE2004/001144 priority patent/WO2005009968A1/en
Priority to CNA2004800220985A priority patent/CN1829694A/zh
Priority to IL172826A priority patent/IL172826A0/en
Priority to CO06006724A priority patent/CO5640110A2/es
Priority to ZA200600820A priority patent/ZA200600820B/en
Priority to IS8329A priority patent/IS8329A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
SE0302139A 2003-07-28 2003-07-28 Novel compounds SE0302139D0 (sv)

Priority Applications (16)

Application Number Priority Date Filing Date Title
SE0302139A SE0302139D0 (sv) 2003-07-28 2003-07-28 Novel compounds
CNA2004800220985A CN1829694A (zh) 2003-07-28 2004-07-21 喹啉衍生物和它们在治疗中的用途
RU2006102127/04A RU2006102127A (ru) 2003-07-28 2004-07-21 Производные хинолина и их применение в терапии
US10/566,320 US20080058293A1 (en) 2003-07-28 2004-07-21 Quinoline Derivates and Their Use in Therapy
BRPI0413094-4A BRPI0413094A (pt) 2003-07-28 2004-07-21 derivados de quinolina e seu uso em terapia
KR1020067001966A KR20060054370A (ko) 2003-07-28 2004-07-21 퀴놀린 유도체 및 치료에 있어서의 그의 용도
EP04749180A EP1651610A1 (en) 2003-07-28 2004-07-21 Quinoline derivates and their use in therapy
JP2006521802A JP2007500187A (ja) 2003-07-28 2004-07-21 キノリン誘導体および治療におけるその使用
AU2004259615A AU2004259615A1 (en) 2003-07-28 2004-07-21 Quinoline derivates and their use in therapy
CA002532154A CA2532154A1 (en) 2003-07-28 2004-07-21 Quinoline derivates and their use in therapy
MXPA06000882A MXPA06000882A (es) 2003-07-28 2004-07-21 Derivados de quinolina y su uso en terapia.
PCT/SE2004/001144 WO2005009968A1 (en) 2003-07-28 2004-07-21 Quinoline derivates and their use in therapy
IL172826A IL172826A0 (en) 2003-07-28 2005-12-26 Quinoline derivates and their use in therapy
CO06006724A CO5640110A2 (es) 2003-07-28 2006-01-25 Derivados de quinolina y su uso en terapia
ZA200600820A ZA200600820B (en) 2003-07-28 2006-01-27 Quinoline derivates and their use in therapy
IS8329A IS8329A (is) 2003-07-28 2006-02-24 Kínólínafleiður og notkun þeirra í meðferð

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0302139A SE0302139D0 (sv) 2003-07-28 2003-07-28 Novel compounds

Publications (1)

Publication Number Publication Date
SE0302139D0 true SE0302139D0 (sv) 2003-07-28

Family

ID=27786663

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0302139A SE0302139D0 (sv) 2003-07-28 2003-07-28 Novel compounds

Country Status (16)

Country Link
US (1) US20080058293A1 (sv)
EP (1) EP1651610A1 (sv)
JP (1) JP2007500187A (sv)
KR (1) KR20060054370A (sv)
CN (1) CN1829694A (sv)
AU (1) AU2004259615A1 (sv)
BR (1) BRPI0413094A (sv)
CA (1) CA2532154A1 (sv)
CO (1) CO5640110A2 (sv)
IL (1) IL172826A0 (sv)
IS (1) IS8329A (sv)
MX (1) MXPA06000882A (sv)
RU (1) RU2006102127A (sv)
SE (1) SE0302139D0 (sv)
WO (1) WO2005009968A1 (sv)
ZA (1) ZA200600820B (sv)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
WO2006110516A1 (en) * 2005-04-11 2006-10-19 Abbott Laboratories Acylhydrazide p2x7 antagonists and uses thereof
DK2001474T3 (en) * 2006-03-16 2016-05-09 Second Genome Inc BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND APPLICATIONS THEREOF
DK1937643T3 (en) * 2006-03-16 2016-10-10 Second Genome Inc Bicycloheteroarylforbindelser som p2x7-modulatorer og anvendelser deraf
US20080058309A1 (en) * 2006-07-27 2008-03-06 Astrazeneca Ab Novel Compounds 171
BRPI0809106A2 (pt) * 2007-03-22 2014-08-26 Astrazeneca Ab Derivados de quinolina para o tratamento de doenças inflamatórias
US8106073B2 (en) 2007-11-30 2012-01-31 Astrazeneca Ab Quinoline derivatives 057
CN102046240B (zh) 2008-03-25 2014-06-25 阿费克蒂斯药品公司 新的p2x7r拮抗剂及其应用
DK2243772T3 (da) 2009-04-14 2012-02-13 Affectis Pharmaceuticals Ag Hidtil ukendte P2X7R-antagonister og deres anvendelse
KR101494059B1 (ko) * 2009-12-17 2015-02-16 머크 샤프 앤드 돔 코포레이션 퀴놀린 아미드 ｍ1 수용체 양성 알로스테릭 조절제
CN102858741A (zh) 2010-05-14 2013-01-02 阿费克蒂斯制药股份公司 制备p2x7r拮抗剂的新方法
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
BR112014001454A2 (pt) 2011-07-22 2017-06-27 Actelion Pharmaceuticals Ltd derivados de amidas heterocíclicas como antagonistas do receptor de p2x7
KR102033190B1 (ko) 2012-01-20 2019-10-16 이도르시아 파마슈티컬스 리미티드 Ｐ２ｘ７ 수용체 길항제로서의 헤테로시클릭 아미드 유도체
US9718774B2 (en) 2012-12-12 2017-08-01 Idorsia Pharmaceuticals Ltd Indole carboxamide derivatives as P2X7 receptor antagonist
EP2935211B1 (en) 2012-12-18 2016-11-09 Actelion Pharmaceuticals Ltd. Indole carboxamide derivatives as p2x7 receptor antagonists
KR102222220B1 (ko) 2013-01-22 2021-03-03 이도르시아 파마슈티컬스 리미티드 Ｐ2ｘ7 수용체 길항제로서의 헤테로시클릭 아미드 유도체
CA2897459C (en) 2013-01-22 2021-03-02 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
EP3152192A1 (en) * 2014-06-05 2017-04-12 Merck Patent GmbH Novel quinoline derivatives and their use in neurodegenerative diseases
EP3609868B1 (en) * 2017-03-13 2023-10-18 RaQualia Pharma Inc. Tetrahydroquinoline derivatives as p2x7 receptor antagonists
CN111777638B (zh) * 2020-05-22 2023-05-09 瀚海新拓(杭州)生物医药有限公司 喹啉类化合物、其制备方法、药物组合物和用途
CN114989082A (zh) * 2022-06-30 2022-09-02 华东理工大学 基于i价铜化物和三取代膦协同催化的羟氯喹的高效制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471491A (en) * 1967-08-28 1969-10-07 Squibb & Sons Inc Adamantyl-s-triazines
US3464998A (en) * 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
US4751292A (en) * 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
ATE148098T1 (de) * 1991-02-21 1997-02-15 Sankyo Co Benzolderivate zum fördern der produktion des nervenwachstumsfaktors
DE69533408T2 (de) * 1994-05-27 2005-09-08 Glaxosmithkline S.P.A. Chinolinderivate als Tachykinin NK3 Rezeptor Antagonisten
AR004735A1 (es) * 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
DE69738949D1 (de) * 1996-05-20 2008-10-09 Darwin Discovery Ltd Chinolincarboxamide als tnf-inhibitoren und als pde-iv inhibitoren
GB0013737D0 (en) * 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
MXPA03011908A (es) * 2001-07-02 2004-06-03 Akzo Nobel Nv Derivados de tetrahidroquinolina.
SE0103836D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
US20080058293A1 (en) 2008-03-06
IL172826A0 (en) 2006-06-11
JP2007500187A (ja) 2007-01-11
AU2004259615A1 (en) 2005-02-03
CO5640110A2 (es) 2006-05-31
CA2532154A1 (en) 2005-02-03
ZA200600820B (en) 2007-04-25
MXPA06000882A (es) 2006-03-30
WO2005009968A1 (en) 2005-02-03
EP1651610A1 (en) 2006-05-03
CN1829694A (zh) 2006-09-06
RU2006102127A (ru) 2006-08-27
KR20060054370A (ko) 2006-05-22
BRPI0413094A (pt) 2006-10-03
IS8329A (is) 2006-02-24

Similar Documents

Publication Publication Date Title
IS6658A (is) Ný efnasambönd
PT1263724E (pt) Novos compostos
SE0302139D0 (sv) Novel compounds
SE0301700D0 (sv) Novel compounds
SE0300480D0 (sv) Novel compounds
SE0302811D0 (sv) Novel compounds
SE0200920D0 (sv) Novel compounds
SE0104140D0 (sv) Novel Compounds
SE0300119D0 (sv) Novel compounds
SE0202133D0 (sv) Novel compounds
ATE433447T1 (de) Pyrimiidinverbindungen
SE0202539D0 (sv) Compounds
SE0103836D0 (sv) Novel compounds
MY128924A (en) Novel compounds
TW200604197A (en) New compounds
TW200740781A (en) Novel compounds
SE0402925D0 (sv) Novel Compounds
SE0101038D0 (sv) Novel compounds
SE0102716D0 (sv) Novel compounds
SE0303280D0 (sv) Novel compounds
GB0120461D0 (en) Novel compounds
SE0401763D0 (sv) Compounds
IL172538A0 (en) Depsipeptide compounds, pharmaceutical compositions containing the same and processes for the preparation thereof
SE9902551D0 (sv) Novel compounds
SE0303090D0 (sv) Novel compounds